Introduction {#s1}
============

Asthma affects 339 million people globally and is increasing in prevalence \[[@C1]\]. Although well-controlled asthma is achievable in most patients, more than half of patients remain poorly controlled \[[@C2]--[@C4]\].

Three evidence-based care gaps are major contributors to poor asthma control \[[@C5], [@C6]\]. 1) Control monitoring: assessment of asthma control using guideline criteria is performed in as few as 1% of clinical encounters \[[@C7]\], resulting in under-recognition of suboptimal control \[[@C2], [@C8]\]. 2) Medication adjustment: only 39% of physicians report basing asthma therapy on guideline recommendations \[[@C8]\], leading to asthma under-treatment \[[@C2], [@C8]\]. 3) Asthma action plan (AAP) delivery: only 4% of primary care physicians report consistently providing a written AAP \[[@C9]\] and only 2% of asthma patients actually receive one \[[@C10]\].

Applying the Knowledge-to-Action Framework \[[@C11]\], we hypothesised that the underlying barriers to these key practices could be addressed by a point-of-care computerised clinical decision support system (CDSS). Given that the majority of patients with asthma are managed in primary care, we designed and integrated a CDSS (the Electronic Asthma Management System (eAMS)) into an electronic medical record (EMR) system. We sought to measure the impact of the eAMS on evidence-based care.

Methods {#s2}
=======

Study design, setting, population {#s2a}
---------------------------------

This was a 2-year prospective interrupted time-series (ITS) design study of usual asthma care (baseline period) (year 1) followed by implementation of the eAMS (intervention period) (year 2). The Canadian study was approved by the St Michael\'s Hospital and Hamilton Integrated Research Ethics Boards, registered at [ClinicalTrials.gov](https://clinicaltrials.gov/) (identifier NCT01070095), and carried out across a convenience sample of two academic primary care sites in Hamilton, ON (population around 550 000) (sites 1 and 2) and one nonacademic primary care site in Brampton, ON (population around 570 000) (site 3). All prescribing clinicians were invited. We developed and validated an EMR search algorithm for asthma \[[@C12]\], and then applied this to the practices of consented clinicians. We included asthma patients aged ≥16 years who understood English and had been on an asthma medication in the prior year. We excluded patients who had been on a chronic obstructive pulmonary disease medication in the prior year \[[@C12]\].

Further details are provided in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02241-2018.figures-only#fig-data-supplementary-materials).

Intervention {#s2b}
------------

### Overview {#s2b1}

During the baseline period, all clinicians were e-mailed a link to an online educational module on how to complete an AAP and paper/electronic copies of a blank AAP. As reported previously, we developed the AAP for this trial through a systematic analysis of existing AAPs \[[@C13]\], patient and provider stakeholder wiki-based collaborative editing, and usability optimisation \[[@C14], [@C15]\]. During the intervention period, the eAMS was available in e-charts of all included patients (access was chart based and not clinician based). The eAMS consisted of: 1) a touch tablet patient questionnaire used in the clinic waiting room, and 2) a five-screen point-of-care CDSS that received and processed questionnaire data to produce decision support integrated into the EMR in real-time ([figure 1](#F1){ref-type="fig"}). We developed the eAMS user interface through serial testing and user feedback, and implemented it through rounds presentations before and after launch, written pamphlets, and online resource materials.

![Electronic Asthma Management System (eAMS) schematic. EMR: electronic medical record; AAP: asthma action plan. The eAMS started with a touch tablet patient questionnaire used in the clinic waiting room, which collected asthma symptoms according to Canadian guideline-recommended criteria, medications and details required for AAP personalisation (patient-specific symptoms, activities, triggers and allergies). Next, these data were processed by an evidence-based computerised clinical decision support system in real-time, and guidance regarding asthma control status, corresponding medication change recommendations and an auto-populated, personalised AAP were then integrated into the clinician-facing EMR system.](ERJ-02241-2018.01){#F1}

### Patient questionnaire {#s2b2}

We developed the patient questionnaire and optimised content and usability through serial focus groups with asthma patients (described elsewhere \[[@C16], [@C17]\]), as previously recommended \[[@C18]\]. The questionnaire required 5--10 min to complete, and ascertained asthma control (using Canadian guideline-recommended symptom-based criteria) \[[@C19]\], medication use and details required for AAP personalisation (*e.g.* symptoms, activities (including sports), triggers and allergies). Patients were provided with the tablet questionnaire by a clinic staff member (*e.g.* receptionist) upon arrival for their appointment. An embedded questionnaire message encouraged patients to prompt their practitioner to provide an AAP.

### Clinical decision support system {#s2b3}

Upon opening the chart of any patient who had completed the questionnaire, clinicians saw a notification indicating the patient\'s current asthma control and prompting them to open the CDSS. The CDSS provided: the patient\'s control criteria and self-reported medication use (screen 1); evidence-based medication escalation/de-escalation recommendations (screen 2); AAP yellow zone (acute loss of control zone) medication recommendations (screen 3); a pre-populated AAP (screen 4); and a reminder to book follow-up and provide a pre-printed sticky note with an educational website URL (screen 5) (the website included inhaler technique videos and a self-directed web-based asthma educational programme) \[[@C20]\]. If users progressed through at least one of these screens, a documentation note was automatically written to the EMR chart. If clinicians approved the AAP, it was sent to the chart for printing.

The CDSS development process is described elsewhere \[[@C21]--[@C23]\]. This included development of medication escalation/de-escalation logic rules through a review of existing international asthma guidelines \[[@C21]\], establishment of evidence-based rules for AAP yellow zone medications through a systematic review \[[@C22]\], and application of evidence-based methods to optimise the language and format of provided guidance \[[@C23]\]. The AAP populated by the eAMS was the same as that used in the baseline phase (see earlier details).

Further intervention details are provided in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02241-2018.figures-only#fig-data-supplementary-materials).

Outcomes {#s2c}
--------

Four trained reviewers performed an electronic chart audit of all outpatient visits and asthma-related telephone interactions (details in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02241-2018.figures-only#fig-data-supplementary-materials)). The primary outcome was AAP delivery, measured by the proportion of patients/visits with written AAP delivery during the intervention *versus* baseline period (comparison of cumulative proportion of patients receiving an AAP; ITS analysis with autoregressive integrated moving average (ARIMA) model for visits with AAP delivery). Secondary outcomes included comparison of the cumulative proportion of patients/visits with asthma control determined according to symptom-based criteria (control determination required meeting one or more criteria for uncontrolled asthma or all criteria for controlled asthma; see [supplementary table S1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02241-2018.figures-only#fig-data-supplementary-materials)) and the proportion of patients/visits with escalation of controller therapy (including initiation of controller therapy) during the intervention *versus* baseline period. We attempted to identify predictors of these outcomes through a generalised linear mixed model (GLMM) including the following candidate parameters, defined *a priori*: clinic, appointment provider practitioner type, prior objective diagnosis of asthma, documented physician diagnosis of asthma, presenting complaint type, billing physician (most responsible physician/other), previous emergency department visit(s)/hospitalisation(s) for asthma and current asthma control. We compared the proportion of oral corticosteroid prescriptions and rescue to controller medication prescriptions between periods. During the intervention period, we measured the proportion of visits where patients had good control in which medications were de-escalated, the proportion of patients in whom discussions about medication adherence took place and system uptake.

Analysis {#s2d}
--------

The intervention period included all visits that occurred while all components of the eAMS were active, in each respective clinic. We compared patient variables between baseline and intervention periods with Fisher\'s exact/Chi-squared tests and ANOVAs, as appropriate. We compared outcome proportions between periods with Chi-squared tests. AAP delivery measured the proportion of patients on an asthma controller medication for at least one visit who received an AAP (excluding those who had received/reviewed an AAP in the last 6 months). In the ITS analysis, we compared outcomes rates in 26 consecutive 2-week intervals prior to the intervention to those in 26 consecutive 2-week intervals following the intervention, using an ARIMA model. Model checking included autocorrelation and partial autocorrelation plots, and the Augmented Dicky--Fuller test and Ljung--Box test. In measuring asthma control assessment, we eliminated visits in which control had been assessed within 28 days \[[@C5]\]. In measuring therapy escalation, we eliminated visits in which escalation had been made within 3 months. To account for individual and clinical risk factors as well as the longitudinal component, we used a GLMM with a logit link to identify predictors of main outcomes among patients seen in both the baseline and intervention periods. A random effect was included to account for within-subject correlation (confidence intervals were bootstrapped). Analyses were performed using R version 3.4.0 ([www.r-project.org](https://www.r-project.org/)). Statistical significance was defined at a two-sided 0.05 level. Sample size calculations and further analytical details are presented in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02241-2018.figures-only#fig-data-supplementary-materials).

Results {#s3}
=======

Chart review {#s3a}
------------

Agreement between reviewers in chart abstraction was 82.8--97.3% for control criteria, 97.5% for assessment of medication changes and 100% for AAP delivery (the κ statistic could not be computed due to perfect agreement for the primary outcome).

Population {#s3b}
----------

We recruited 19 out of 37 (51.4%) approached physicians and one out of three (33%) approached nurse practitioners (NPs). One physician withdrew consent before intervention launch, leaving 18 out of 37 (48.4%) physicians. The NP managed patients from an additional five physicians, enabling us to include patients from 23 out of 37 (62.2%) physicians. These physicians had been in practice for 16.1±8.9 years (mean±[sd]{.smallcaps}; range 2--33 years) and 15 out of 23 were female (65.2%). They were the most responsible physician for 830 eligible patients seen in the baseline period (3565 eligible visits) and 890 seen in the intervention period (3444 eligible visits) ([table 1](#TB1){ref-type="table"}). There were 1272 unique patients seen over the study period, with 382 (30.0%) seen exclusively in the baseline period, 442 (34.8%) seen exclusively in the intervention period and 448 (35.2%) seen in both periods. Given that patients occasionally saw clinicians other than their most responsible physician for urgent issues, these patients received care from 237 unique providers: 156 residents, 60 staff physicians (41 (68.3%) female, in practice for 16.6±11.8 years (mean±[sd]{.smallcaps}; range 2--52)), 20 NPs and three physician assistants. Each provider averaged 29.6±58.2 visits (mean±[sd]{.smallcaps}; range 1--439). In the baseline period, 140 out of 3565 (3.9%) visits were related to asthma compared with 158 out of 3444 (4.6%) visits in the intervention period (p=0.19) and 276 out of 830 (33.3%) patients had at least one visit for a respiratory complaint compared with 281 out of 890 (31.6%) in the intervention period (p=0.49).

###### 

Patient characteristics

  **Characteristic**                                    **Baseline period**   **Intervention period**   **p-value**
  ---------------------------------------------------- --------------------- ------------------------- -------------
  **Subjects**                                                  830                     890            
  **Age years**                                              45.9±17.4               47.3±17.2             0.084
  **Female**                                                602 (72.5)              632 (71.0)             0.519
  **Smoking status**                                                                                       0.001
   Nonsmoker                                                411 (49.5)              460 (51.7)         
   Ex-smoker                                                161 (19.4)              185 (20.8)         
   Current smoker                                           124 (14.9)              157 (17.6)         
   Not documented                                           134 (16.1)               88 (9.9)          
  **Comorbidities**                                                                                    
   Atopy                                                    331 (39.9)              350 (39.3)             0.285
   COPD                                                      62 (7.5)                68 (7.6)              0.966
   Other respiratory diagnosis                               16 (1.9)                13 (1.5)              0.573
  **Prior objective testing**                                                                          
   Spirometry                                               529 (63.7)              579 (65.1)             0.600
   Methacholine challenge                                    74 (8.9)                73 (8.2)              0.658
  **Prior asthma care (since 2003)**                                                                   
   Seen by pulmonologist or allergist                       136 (16.4)              158 (17.8)             0.491
   Seen in emergency room or hospitalised for asthma         51 (6.1)                38 (4.3)              0.100
  **Baseline medications (first study visit)^\#^**                                                     
   Short-acting bronchodilator                              469 (56.5)              544 (61.1)             0.058
   Inhaled corticosteroid alone^¶^                          147 (17.7)              173 (19.4)             0.391
   Inhaled corticosteroid with long-acting β-agonist        125 (15.1)              158 (17.8)             0.150
   Long-acting β-agonist alone                                6 (0.7)                 4 (0.4)              0.669
   Leukotriene receptor antagonist                           21 (2.5)                26 (2.9)              0.727
   Long-acting muscarinic antagonist                          6 (0.7)                13 (1.5)              0.218
   Prednisone^+^                                              8 (1.0)                 6 (0.7)              0.689

Data are presented as n, mean±[sd]{.smallcaps} or n (%), unless otherwise stated. COPD: chronic obstructive pulmonary disease. ^\#^: formal assessment of asthma severity was not possible, as this requires knowledge of which medications are required to achieve good control and asthma control itself was not known for most patients (a breakdown of baseline medications by control status is provided in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02241-2018.figures-only#fig-data-supplementary-materials)); ^¶^: without concurrent use of a long-acting β-agonist in a combination inhaler or as a separate inhaler; ^+^: includes only those patients using prednisone chronically.

System uptake {#s3c}
-------------

In the intervention period, 551 out of 890 (61.2%) patients completed the questionnaire at least once. Clinicians accessed the CDSS in 174 of the 505 patients (34.4%) in whom actions were required. A detailed mixed methods system uptake analysis will be reported separately.

Primary outcome {#s3d}
---------------

The proportion of patients on a controller medication who received an AAP was zero out of 412 (0%) in the baseline period and 79 out of 443 (17.8%) in the intervention period (absolute increase 0.18 (95% CI 0.14--0.22)). In the ITS analysis, there was an increase in the proportion of visits where patients received an AAP from zero at baseline to 0.305 at the time of intervention (p\<0.0001) ([figure 2](#F2){ref-type="fig"}). There was no significant decreasing trend as the intervention period progressed (p=0.17). Modelling was not possible due to the absence of AAP delivery in the baseline period.

![Time-series analysis. AAP: asthma action plan; eAMS: Electronic Asthma Management System. The proportion of asthma patient visits in which an AAP was delivered, at each 2-week interval (baseline period: intervals 0--26; intervention period: intervals 26--52). The arrow indicates the period in which the eAMS intervention was launched.](ERJ-02241-2018.02){#F2}

Secondary outcomes {#s3e}
------------------

### Asthma control monitoring {#s3e1}

Practitioners determined asthma control according to symptom-based criteria in 173 out of 3497 (4.9%) eligible visits in the baseline period and 849 out of 3062 (27.7%) in the intervention period (p\<0.001). Control was determined at least once in 118 out of 830 (14.2%) and 523 out of 890 (58.8%) patients, respectively (p\<0.001). After adjusting for other variables, control was more likely to be ascertained during the intervention period (OR 8.62 (95% CI 5.14--12.45)) ([table 2](#TB2){ref-type="table"}).

###### 

Predictors of asthma control assessment

                                                                   **Control not assessed**   **Control assessed**   **GLMM model OR (95% CI)**
  --------------------------------------------------------------- -------------------------- ---------------------- ----------------------------
  **Visits**                                                                 5537                     1022                    4143^\#^
  **Period**^¶^                                                                                                     
   Baseline                                                              3324 (95.1)               173 (4.9)        
   Intervention                                                          2213 (72.3)               849 (27.7)            8.51 (5.51--11.52)
  **Clinic**                                                                                                        
   1                                                                     2290 (79.8)               578 (20.2)       
   2                                                                     1052 (86.4)               166 (13.6)            0.63 (0.46--0.90)
   3                                                                     2195 (88.8)               278 (11.2)            0.28 (0.21--0.41)
  **Practitioner type**                                                                                             
   Physician                                                             2705 (84.9)               481 (15.1)       
   Nurse practitioner                                                     506 (88.9)               63 (11.1)             0.93 (0.59--1.49)
   Resident                                                              1924 (82.0)               423 (18.0)            1.38 (0.99--1.86)
   Physician assistant                                                    402 (88.2)               54 (11.8)             1.22 (0.74--2.01)
  **Objective asthma diagnosis**                                                                                    
   No                                                                    3308 (85.2)               576 (14.8)       
   Yes                                                                   2229 (83.3)               446 (16.7)            0.78 (0.61--0.99)
  **Physician-documented asthma diagnosis**                                                                         
   No                                                                    2251 (88.8)               283 (11.2)       
   Yes                                                                   3286 (81.6)               739 (18.4)            1.35 (1.01--1.75)
  **Presenting complaint**                                                                                          
   Asthma                                                                 148 (54.6)               123 (45.4)       
   Nonrespiratory                                                        4874 (87.7)               684 (12.3)            0.11 (0.08--0.18)
   Respiratory (nonasthma)                                                515 (70.5)               215 (29.5)            0.65 (0.43--1.06)
  **Previous emergency department visit(s)/hospitalisation(s)**                                                     
   No                                                                    5278 (84.8)               948 (15.2)       
   Yes                                                                    259 (77.8)               74 (22.2)             1.97 (1.18--3.06)
  **Seen by most responsible physician**                                                                            
   No                                                                    3676 (84.0)               701 (16.0)       
   Yes                                                                   1861 (85.3)               321 (14.7)            1.12 (0.83--1.53)

Data are presented as n or n (%), unless otherwise stated. GLMM: generalised linear mixed model. ^\#^: the model included only the 448 subjects seen in both the baseline and intervention periods (4143 total visits); ^¶^: both in the baseline and intervention periods, there was no association between time and the outcome.

### Controller therapy escalation {#s3e2}

Practitioners escalated controller therapy in 108 out of 3422 (3.2%) eligible visits in the baseline period and 126 out of 3240 (3.9%) in the intervention period (p=0.12). At least one therapeutic escalation occurred in 106 out of 830 (12.8%) and 117 out of 890 (13.1%) patients, respectively (p=0.87). After adjusting for other variables, therapy was less likely to be escalated during the intervention period (OR 0.55 (95% CI 0.28--0.99)) ([table 3](#TB3){ref-type="table"}). In the baseline period, a short-acting β-agonist alone was added to therapy in 62 visits and a controller medication added in 54 visits (ratio 1.15) compared with 33 and 229 visits in the intervention period, respectively (ratio 0.14) (p\<0.001). Oral corticosteroids were prescribed in 28 out of 3565 (0.79%) visits and 24 out of 830 (2.89%) patients in the baseline period, and in 16 out of 3444 (0.46%) visits (p=0.089) and 15 out of 890 (1.69%) patients (p=0.093) in the intervention period.

###### 

Predictors of controller therapy escalation

                                                                   **Controller escalation not made**   **Controller escalation made**   **GLMM model OR (95% CI)**
  --------------------------------------------------------------- ------------------------------------ -------------------------------- ----------------------------
  **Visits**                                                                      6428                               234                          4204^\#^
  **Period**^¶^                                                                                                                         
   Baseline                                                                   3314 (96.8)                         108 (3.2)             
   Intervention                                                               3114 (96.1)                         126 (3.9)                  0.55 (0.28--0.99)
  **Clinic**                                                                                                                            
   1                                                                          2947 (97.7)                          67 (2.3)             
   2                                                                          1244 (97.6)                          31 (3.4)                  0.82 (0.42--1.44)
   3                                                                          2237 (94.3)                         136 (5.7)                  2.19 (1.51--3.53)
  **Practitioner type**                                                                                                                 
   Physician                                                                  3087 (96.0)                         130 (4.0)             
   Nurse practitioner                                                          547 (96.5)                          20 (3.5)                  0.82 (0.38--1.74)
   Resident                                                                   2368 (97.3)                          66 (2.7)                  0.79 (0.46--1.41)
   Physician assistant                                                         425 (95.9)                          18 (4.1)                  0.55 (0.19--1.16)
  **Objective asthma diagnosis**                                                                                                        
   No                                                                         3736 (95.9)                         158 (4.1)             
   Yes                                                                        2692 (97.3)                          76 (2.7)                  0.46 (0.31--0.68)
  **Physician-documented asthma diagnosis**                                                                                             
   No                                                                         2507 (97.7)                          60 (2.3)             
   Yes                                                                        3921 (95.8)                         174 (4.2)                  1.35 (0.90--2.05)
  **Presenting complaint**                                                                                                              
   Asthma                                                                      201 (76.4)                         62 (23.6)             
   Nonrespiratory                                                             5610 (98.5)                          85 (1.5)                  0.06 (0.04--0.10)
   Respiratory (nonasthma)                                                     617 (87.6)                         87 (12.4)                  0.51 (0.33--0.85)
  **Previous emergency department visit(s)/hospitalisation(s)**                                                                         
   No                                                                         6096 (96.5)                         221 (3.5)             
   Yes                                                                         332 (96.2)                          13 (3.8)                  1.18 (0.36--2.25)
  **Seen by most responsible physician**                                                                                                
   No                                                                         4308 (96.6)                         151 (3.4)             
   Yes                                                                        2120 (96.2)                          83 (3.8)                  0.89 (0.58--1.45)
  **Current level of asthma control**                                                                                                   
   Not documented                                                             4587 (97.5)                         117 (2.5)             
   Poor control                                                               1302 (92.4)                         107 (7.6)                  2.23 (1.52--3.30)
   Good control                                                                539 (98.2)                          10 (1.8)                  0.52 (0.09--1.15)

Data are presented as n or n (%), unless otherwise stated. GLMM: generalised linear mixed model. ^\#^: the model included only the 448 subjects seen in both the baseline and intervention periods (4204 total visits); ^¶^: both in the baseline and intervention periods, there was no association between time and the outcome.

In the intervention period, clinicians de-escalated therapy in seven out of 459 (1.5%) visits in which asthma control was adequate and documented medication adherence discussions in 219 out of 890 (24.6%) patients.

On-treatment analysis {#s3f}
---------------------

Counting only intervention period visits in which patients completed the questionnaire and the notification prompted clinicians to open the CDSS to take action, 81 out of 265 (30.6%) patients received an AAP, control was assessed in 656 out of 770 (85.2%) visits and medications were escalated in 69 out of 1001 (6.9%) visits.

Discussion {#s4}
==========

We demonstrated that an evidence-based CDSS improves the quality of asthma care in real-world primary care settings while requiring minimal changes to local resources for successful implementation.

AAP delivery increased from zero at baseline to 17.8% of patients and 30.5% of visits with the intervention. Our nil baseline rate was comparable to the 2% rate described in a previous primary care chart audit \[[@C10]\]. Guidelines dating back to the 1990 British Asthma Guideline \[[@C24]\] and the 1996 Canadian Asthma Guideline \[[@C25]\] call for all patients to receive a written AAP. The majority of physicians consider AAPs important, but fail to provide them due to lack of time and confidence in generating AAP recommendations \[[@C8], [@C26]\]. Although we previously published basic principles for populating the AAP yellow zone \[[@C22]\], experts suggested that an information technology approach would be essential to operationalising these in the real world \[[@C18]\]. Correspondingly, the eAMS targeted time and knowledge/skill barriers by leveraging the CDSS to auto-populate the AAP. Studies have also shown that when AAPs are tailored and provided along with education, patients view them favourably and are more adherent \[[@C27]\]. The eAMS created a highly personalised AAP reflecting self-described symptoms, activities and triggers, and provided access to an asthma education programme. A primary care study identified the following enablers of AAP delivery: patients requesting an AAP, adding a blank AAP to the chart and receiving a completed copy of the AAP \[[@C9]\]. Indeed, the eAMS questionnaire asked patients to prompt their practitioners to provide them with the AAP and the CDSS auto-completed a blank AAP for clinicians.

Asthma control monitoring also improved with the intervention. Control was assessed in 4.9% of baseline visits, comparable to a US primary care chart review in which all control criteria were assessed in 1% of patients \[[@C7]\]. In a UK review, only 27% patients who died of asthma had had control assessed at their most recent primary care visit \[[@C28]\]. Improving control monitoring could improve health-related quality of life, avoid lost productivity and reduce healthcare costs through better disease management and adherence \[[@C29]\], although barriers are multi-fold. Physicians often pose an open-ended control question (*e.g.* "How is your asthma") \[[@C8]\]. However, most patients are unaware of their poor control. In a European survey of 8000 patients with asthma, 20.1% had controlled asthma, yet 90.5% self-identified as well controlled \[[@C4]\]. Correspondingly, a failure to probe each control parameter leads to under-reporting of poor control \[[@C8]\]. Physicians may also overestimate control. In a practice-based assessment, physicians labelled 31% of their inadequately controlled patients as "well controlled" \[[@C2]\]. Failure to assess control objectively may be due to lack of familiarity with criteria. Canadian primary care physicians identified an average of 2.2 out of eight control criteria \[[@C30]\] and 26% of US primary care physicians were confident that they could assess asthma control \[[@C7]\]. Additional barriers include lack of time and simply forgetting to assess control \[[@C30]\]. The eAMS attempted to address these barriers by posing control questions in the patient questionnaire and "pushing" results to clinicians.

We did not identify a higher proportion of controller medication escalations with the intervention. The eAMS attempted to address known barriers to appropriate adjustment, including failure to recognise poor control and lack of knowledge regarding asthma pharmacotherapeutics \[[@C31]\]. However, patient factors including inhaled corticosteroid aversion and affordability may also play a role \[[@C8]\]. We noted that presenting clinicians with patient-reported medication use (CDSS screen 1) led to discussions about adherence in 24.6% of patients. Given reported controller adherence rates of only 30--40% \[[@C32]\], it is conceivable that adherence counselling discussions obviated the need for medication escalation in many patients. There was an improvement in the ratio of rescue to controller medication prescriptions in the intervention period (a metric associated with reduced healthcare utilisation and systemic steroid requirements) \[[@C33]\]. This suggests that although the quantity of prescriptions did not improve, their quality may have. We also note that therapeutic de-escalations occurred in only 1.5% of visits in which asthma control was adequate, despite eAMS recommendations for de-escalation. Determinants of de-implementation may be different than those of implementation and require further study.

Other asthma care CDSSs have been reported. Between two 2014 systematic reviews of trials of airways disease-related e-health interventions, we identified three included studies describing EMR-integrated clinician-facing CDSSs that provided complex patient-tailored decision support (beyond simple reminders) for nonemergent adult asthma management \[[@C34], [@C35]\]. T[ierney]{.smallcaps} *et al.*\'s \[[@C36]\] system used EMR data to generate suggestions regarding immunisation, prescriptions and smoking cessation (no AAP), and showed no effects on guideline-based care. K[uilboer]{.smallcaps} *et al.*\'s \[[@C37]\] system used EMR data to generate critiques of physician treatments (no AAP), demonstrating increased lung function testing and reduced cromogylate prescriptions. Finally, P[laza]{.smallcaps} *et al.*\'s \[[@C38]\] system used chart and clinician-entered data to determine asthma control and provide corresponding medication recommendations (no AAP). They demonstrated improved pharmacotherapy and symptoms, but results were confounded by a concurrent nurse education programme \[[@C38]\]. More recently, T[amblyn]{.smallcaps} *et al.* \[[@C39]\] reported a system comparable to ours that assessed control, provided medication recommendations and auto-populated an AAP. The system estimated control on the basis of rescue medication refills and healthcare utilisation from administrative databases, requiring clinician entry for other control criteria. In a randomised controlled trial, the primary outcome (out-of-control asthma events) did not differ between groups, although as in our study the ratio of short-acting β-agonist to controller medication prescriptions improved \[[@C39]\]. K[uhn]{.smallcaps} *et al.* \[[@C40]\] described an electronic AAP that required physician activation and data entry. In an observational study, an "on-treatment" analysis suggested lower oral corticosteroid requirements and exacerbations among children (but not adults). Although these two studies provided an auto-populated AAP, neither used a validated or personalised AAP designed with human factors optimisation (as our tool does). Furthermore, none of the aforementioned systems engaged patients to reduce data collection and entry burdens on clinicians (addressed through the pre-visit questionnaire in our tool), therefore failing to address clinician time constraints at the point of care \[[@C40]\]. Qualitative studies confirm that even when CDSSs improve care, time constraints are a critical barrier to their usage \[[@C41]\].

Clinicians accessed the eAMS in 34.4% of patients in whom actions were required. This uptake rate compares favourably with that of previous asthma CDSSs \[[@C35]\]. Among evidence-based predictors of successful CDSSs presented in the recent GUIDES checklist \[[@C42]\], the eAMS includes automatic prompting (a "push" strategy), "just in time" information delivery (during the clinical visit), clinical workflow integration (integration with existing EMR), patient-targeted information, patient-mediated clinician prompts and individualised recommendations. Strategies to drive improvement may include formal usability and workflow analysis and optimisation \[[@C42]\], features to address multiple morbidities, prompts/advice that can be tailored to clinician preferences, detailed explanations/references for recommendations, and a requirement that practitioners supply a reason for over-riding advice \[[@C42]\].

Our study has several limitations. Measurements of control assessment may have been underestimated due to poor chart documentation. However, we believe that clinicians would be very likely to document poor control if ascertained, given its clinical relevance and influence on treatment decisions. An ITS design is vulnerable to temporal factors affecting behaviour. To the best of our knowledge, no such changes (*e.g.* changes in payment models, new educational programmes or allied health support) occurred during the study. We chose behavioural outcomes based on guideline recommendations and known correlations to patient outcomes, but did not directly measure patient outcomes.

In summary, we describe improvements in the quality of asthma care after implementation of a complex e-health intervention in a real-world setting. System improvements may be considered to further drive uptake and a future randomised controlled trial should assess impact on patient-level outcomes.
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